Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Novo

Novo Nordisk is losing Canadian patent protection on a blockbuster drug after not paying a small fee

“I’m sure someone’s lost their job,” said the CEO of Sandoz, which has now filed to launch a generic GLP-1 drug in Canada next year.

Fortune

With Novo Nordisk's CEO Out, Wall Street Wants an American Leader

With its stock plummeting over the past year, Novo Nordisk is waving goodbye to its top executive. What might the future hold for the weight-loss drug kingpin?

MarketBeat

Wegovy use spikes among teens as doctors grapple with obesity crisis

New data indicates that American teenagers are increasingly using the weight-loss drug Wegovy, as confidence in its use for young people with obesity grows among families and doctors.

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Eli Lilly vs. Novo Nordisk: Which Stock Is the Winner of the Weight-Loss Drug Boom?

Both companies have established a solid presence in the weight-loss drug market, but only one of them can lead.

Barchart

“A huge Achilles heel with the non-traditionals”: What’s the hardest part about designing a fresh guitar? According to Novo Guitars, it’s probably not one you’d expect

This particular component accounts for “80%” of a new design's success, according to Novo’s Travis Tingley and session ace JD Simo

Guitar World

Wegovy maker Novo Nordisk cuts profit forecast as US prescriptions tail off

Slowdown will deepen concerns Denmark’s biggest company is losing market share to US rival Eli Lilly

The Guardian - UK

Is Eli Lilly a Buy After Weak Earnings and CVS-Novo Partnership?

Shares of Eli Lilly just got walloped. So, is the company still the name to own in GLP-1s, or are the tables turning on this pharma giant?

MarketBeat

Read news from The Economist, FT, and more,
with one subscription

The Top 3 Stock Picks at the World’s Greatest Hedge Fund

See which three stocks the world's most successful hedge fund, which generated returns of +30% for decades, had the biggest stakes in at the end of 2024.

MarketBeat

Novo Nordisk shares post the biggest monthly decline since 2002

Novo Nordisk’s stocks experienced the sharpest monthly decline since July 2002 due to growing competition and several disappointing trial results. However, analysts remain optimistic about the shares, forecasting a potential price upside of up to 60% over the next 12 months.

Euronews

Ozempic ingredient linked to dangerous eye condition that could threaten sight

Higher risk of developing nonarteritic anterior ischemic optic neuropathy found in study

The Independent UK

Is Viking Therapeutics the Next Blockbuster GLP-1 Stock?

Viking Therapeutic may have a GLP-1 blockbuster on their hands with VK2735 as it produces weight loss at 5X the speed of Novo Nordisk's Wegovy GLP-1 drug.

MarketBeat

Despite Challenges Novo Nordisk Plans to Crush GLP-1 Competitors

Novo Nordisk slashed prices on its GLP-1 obesity drugs as it launches NovoCare to gain compounded GLP-1 users as the compounding labs face deadlines to cease.

MarketBeat

Novo Nordisk cuts Wegovy prices, following similar move by Zepbound-maker Eli Lilly

Makers of the popular obesity treatments Wegovy and Zepbound are cutting prices for people without insurance

The Independent UK

Wall Street’s Most Wanted: 2 Highly Shorted Stocks Right Now

See why these two high-flying stocks are among the most shorted in the market, plus counterarguments amid bearish gripes.

MarketBeat

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat

These 3 Stocks Just Announced Major Dividend Hikes

See which three stocks just raised their dividend payments by over 15%. On firm now has a sky-high indicated yield of over 10%.

MarketBeat

Novo Nordisk Shares Near New 52-Week Low: Analysts See Big Upside

Novo Nordisk shares are closing in on a new 52-week low. Is the stock gearing up for a recovery with sentiment currently low?

MarketBeat

Will Eli Lilly Stock Keep Climbing? Q2 Trial Results Are Crucial

Eli Lilly is still seeing rapid sales growth for its diabetes and weight loss drugs. However, one drug waiting in the wings hopes to be its next blockbuster.

The Guardian - UK

Novo Nordisk confident despite Trump tariff risk as sales of weight-loss jab soar

Europe’s biggest firm, whose sales of Wegovy almost doubled, feels it can ‘meet demands’ of US administration

Get all your
news in one place.

100's of premium titles.
One news app.

Fortune

Novo Nordisk CFO says drugmaker focusing on next generation of weight loss drugs

Novo Nordisk's Karsten Munk Knudsen is targeting 800 million obese people globally.

Fortune

Investors grow anxious at Novo Nordisk's silence over CagriSema weight loss results

Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.

Fortune

Novo Nordisk stock surges 7% on new weight-loss drug update

The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger.

MarketBeat

Ultrasound Weight Loss: GE HealthCare and Novo Nordisk’s Play

GLP-1 drugs have been all the rage for weight loss, but GE Healthcare and Novo Nordisk are working on a non-invasive approach to controlling metabolic functions

Guitar World

“There was unfinished business. I was hoping to have the opportunity to reclaim my name someday”: Revered luthier Dennis Fano is now leading both Fano and Novo – as his two boutique companies merge

Both firms were founded by Fano, and now they’ve been brought under one leadership structure for the first time

Barchart

Trump Wants Greenland. Why That Could Be Bad News for Novo Nordisk Stock.

The pharma giant’s stock has been under pressure since the Greenland issue has been in the spotlight.

The Guardian - UK

Wegovy maker Novo Nordisk sponsored British pharmacies in pursuit of sales

Danish drug company gave money for Google ads to promote weight loss services and received data on web traffic and prescriptions

1 … 4 5 6 7

People

Donald Trump

198,361 stories

Lars Fruergaard Jørgensen

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.